Novartis Capital
Novartis Capital Corp operates as a specialized corporate financing and debt-issuing subsidiary supporting Novartis AG, a major Swiss multinational pharmaceutical enterprise headquartered in Basel, Switzerland. The overarching parent corporation researches, develops, manufactures, and markets innovative prescription medicines across critical therapeutic areas including oncology, immunology, neuroscience, and cardiovascular health. Principal revenue for the group is derived through global wholesale pharmaceutical sales to healthcare distributors, pharmacies, and hospitals. Novartis Capital Corp acts as a dedicated funding vehicle to issue bonds and manage capital market credit facilities.
9 of the funds FundTelligence covers report a position in Novartis Capital.
- Legal name
- Novartis Capital Corp
- Sector
- Financials
- Country
- United States
- Funds holding it
- 9
Funds holding Novartis Capital
- Nordea BetaPlus Enhanced US Corporate Bond — Nordea Funds · 1.02 % (full portfolio disclosed, September 2026)
- Mercer Short Duration Global Bond Fund 1 — Mercer · 0.91 % (full portfolio disclosed, December 2025)
- Storebrand Global Corporate Bond IG 4-6Y — Storebrand · 0.69 % (full portfolio disclosed, October 2026)
- Schroder ISF Sustainable Global Multi Credit — Schroders · 0.55 % (full portfolio disclosed, December 2025)
- Storebrand Global Kreditt IG — Storebrand · 0.4 % (full portfolio disclosed, October 2026)
- KLP Obligasjon Global Mer Samfunnsansvar — KLP · 0.31 % (full portfolio disclosed, June 2026)
- KLP Obligasjon Global — KLP · 0.14 % (partially disclosed portfolio, June 2026)
- KLP Obligasjon Global 3 år — KLP · 0.12 % (full portfolio disclosed, June 2026)
Showing the 8 largest of 9 funds holding it.